^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LAVA-051
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
LAVA Therap
Drug class:
γδ TCR modulator, CD1D inhibitor
Related drugs:
2ms
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML (clinicaltrials.gov)
P1, N=16, Terminated, Lava Therapeutics | Phase classification: P1/2 --> P1 | N=102 --> 16 | Active, not recruiting --> Terminated; The decision to discontinue LAVA-051clinical trial follows a recent review of the competitive landscape that has continued to evolve (Business decision). The decision is not due to safety concerns.
Phase classification • Enrollment change • Trial termination
|
LAVA-051
over1year
Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML (clinicaltrials.gov)
P1/2, N=102, Active, not recruiting, Lava Therapeutics | Recruiting --> Active, not recruiting
Enrollment closed
|
LAVA-051
over2years
Lava-051, a Novel Bispecific Gamma-Delta T-Cell Engager (Gammabody), in Relapsed/Refractory MM and CLL: Pharmacodynamic and Early Clinical Data (ASH 2022)
LAVA-051 has been well tolerated early in dose escalation with pharmacodynamics and early clinical signs reflective of its intended MoA. The differentiating importance of these pharmacodynamic parameters with any correlating preliminary antitumor activity will be further elucidated with continued dose escalation by the IV and SC route and in the determination of the RP2D and schedule.
Clinical data • PK/PD data • IO biomarker
|
IL6 (Interleukin 6) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • CD1D (CD1d Molecule)
|
CD1D expression
|
LAVA-051
Share via
